产品
编 号:F521972
分子式:C47H55ClF3N5O6S3
分子量:974.61
产品类型
结构图
CAS No: 923564-51-6
联系客服
产品详情
生物活性:
Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with a Ki of less than 1 nM.
体内研究:
Navitoclax (100 mg/kg;口服;21 天处理) 增强 OSI-744 在体内的活性。作为单一药物,每天单独给予 100 mg/kg Navitoclax 没有显著的抗肿瘤活性,而每天给予 50 mg/kg 的 OSI-744 会在 21 天的处理期间导致显著的肿瘤停滞 (%TGI=52)。值得注意的是,Navitoclax 和 OSI-744 的组合连续 21 天每天服用可使 100% 接受处理的荷瘤小鼠产生 98% 的 TGI 和持久的肿瘤消退。Animal Model:Mice with NCI-H1650 model
Dosage:100 mg/kg
Administration:Orally; daily; for 21 consecutive days
Result:As a single agent, 100 mg/kg alone dosed daily had no significant antitumor activity. Notably, the combination with OSI-744 resulted in 98% TGI and durable tumor regressions in 100% of treated tumor-bearing mice.
体外研究:
Navitoclax (ABT-263) 对大约一半的 PPTP 体外面板细胞系具有活性。面板中所有线条的 IC50 中位数为 1.91 μM。Navitoclax 与化疗药物联用可使大多数卵巢癌细胞系产生协同反应,并增强 SK-OV-3 和 IGROV-1 细胞系中的半胱天冬酶活化。